Clin Gastroenterology H: "Useless" or "no way" - patients with irritable bowel syndrome are willing to take a significant risk of medication for symptom relief

Irritable bowel syndrome (IBS) is mostly due to repeated plant nerve dysfunction, due to long periods of rest is not good, pressure is relatively large caused by insomnia, worry, anxiety, irritability, memory loss and gastrointestinal indigestion function caused by digestive function and endocrine disorders, resulting in intestinal spasms, causing irritable bowel syndrome.
the IBS is close to 14%, and the treatment of the disease has had a significant economic impact on health care.
there is currently no proven treatment for IBS.
all IBS treatments, even dietary therapies, can cause adverse reactions.
, most patients suffer from IBS and are even willing to try various treatments to relieve gastrointestinal symptoms.
study is designed to assess the willingness of IBS patients to take on the risks of medication and the costs they pay to improve their symptoms.
researchers mailed questionnaires on drug risk to IBS patients who met the Rome IV standard and asked them to fill out a survey that collected data on patient demographics, symptoms, drug use, previous adverse drug events and pain catastrophic.
a willingness scale to assess respondents' willingness to take on drug risks, while a series of payment scales quantified the maximum expenditure on hypothetical drugs used to treat IBS.
results showed that the average course of IBS symptoms was 17.7 years among respondents (n s 215; female 81.8%; average age: 57 years).
patients with severe diarrhea reported an average risk of sudden death of 10.2 per cent ±15.7 per cent and a 99 per cent chance of cure.
pain scale scores were not associated with an increased risk of taking the drug.
IBS patients are willing to pay an average of $73 a month (if they earn $75,000 a year) and $197 (if they earn $75,000 a year) for pain medications.
study, researchers found that patients with diarrhea-based IBS were willing to take significant risks to improve their symptoms, while those with catastrophic pain symptoms at IBS were reluctant.
clinicians' knowledge of patients' willingness to take medication risks may help them guide patients' treatment choices.
。